About: http://data.cimple.eu/news-article/55750aab984abb93c881d365294c563690b3356dd780d5adeaf13933

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/55750aab984abb93c881d365294c563690b3356dd780d5adeaf13933 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Johnson & Johnson remains "very confident" in its Covid-19 vaccine and hopeful for a quick resolution from regulators over its status, a top executive said Tuesday. "We remain very confident and very hopeful that the benefit-risk profile will play out," J&J Chief Financial Officer Joseph Wolk told CNBC. The comments came ahead of a decision expected later Tuesday from Europe's drug regulator on the safety of the single-shot innoculation. US pandemic advisor Anthony Fauci said the United States is likely to announce its decision by Friday. Health authorities in the United States on April 14 recommended a pause on the vaccine following six instances of severe blood clots out of nearly seven million Americans who received the vaccine. The company hopes "very shortly ... perhaps as early as the end of this week, to have some resolution with how we are going to proceed," Wolk said. Asked if the US decision to suspend the program hindered public confidence in vaccines, Wolk said "I would hope that at the end of the week, the population in general will feel more confident in taking the vaccine." The comments came as J&J released first-quarter results. An earnings press release did not elaborate on vaccine approval issues, but said the vaccine generated $100 million in revenues in the United States during the period. J&J is selling the vaccine at cost. J&J has also encountered production problems at a Baltimore, Maryland factory managed by Emergent BioSolutions. The Food and Drug Administration has suspended production in the plant pending a review of the facility. Wolk said J&J expects to be "in a position to meet our contract commitments, not just here in the US but across the globe" following the FDA review. jum-jmb/bgs
schema:headline	J&J 'very confident' in vaccine, eyes quick resolution
schema:mentions	Chief financial officer Pistol USA Gymnastics CNBC Johnson & Johnson Baltimore Thrombus Anthony S. Fauci Food and Drug Administration European Union Pandemic Vaccine United States Coronavirus disease 2019 Emergent BioSolutions We Remain
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-04-20 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	positive sentiment
http://data.cimple...readability_score	73 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.123 as of May 22 2025

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3241 as of May 22 2025, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 10 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2026 OpenLink Software